高级检索
当前位置: 首页 > 详情页

Multivalent assembly of nucleolin-targeted F3 peptide potentiates TRAIL's tumor penetration and antitumor effects

文献详情

资源类型:
Pubmed体系:
机构: [1]Division of Liver surgery and NHC Key Lab of Transplant Engineering and Immunology, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China [2]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University, Chengdu 610041, China [3]Department of Laboratory Medicine, the West China Second University Hospital, Sichuan University, Chengdu 610041, China [4]West China-California Research Center for Predictive Intervention Medicine, Chengdu 610041, China [5]Regenerative Medical Research Center, West China Hospital, Sichuan University, Chengdu 610041, China [6]Proteomics-Metabolomics Platform, Core facilities, West China Hospital, Sichuan University, Chengdu 610041, China [7]Precision Medicine Key Laboratory of Sichuan Province and Precision Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China [8]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China [9]SCMPA Key Laboratory for Quality Research and Control of Chemical Medicine, Chengdu Institute for Drug Control, Chengdu 610041, China [10]Department of Ophthalmology, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, China [11]Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China [12]Division of Abdominal Tumor Multimodality Treatment Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
出处:
ISSN:

关键词: Tumor-targeting therapy Tumor penetration Drug delivery Nucleolin F3 peptide TRAIL

摘要:
Tumor-targeting drug delivery holds great promise for cancer treatment but faces significant challenges in penetrating solid tumors to achieve optimal therapeutic efficacy. By harnessing the natural tissue-penetration effect conferred by the CendR motif, we identified that the nucleolin (NCL)-targeted peptide F3 possesses tumor-penetrating capabilities. Co-administration of F3 with doxorubicin and the apoptosis-inducing protein TRAIL enhanced effective tumor penetration and improved antitumor activity. Taking advantage of TRAIL's natural self-trimerization, we developed a novel fusion protein, F3-TRAIL. This design enabled the trivalent assembly of F3 when fused with TRAIL, significantly enhancing its binding to NCL-positive tumor endothelial and parenchymal cells, resulting in deeper tumor penetration and superior antitumor effects compared to TRAIL alone. Mechanistic studies revealed that the multivalent F3-enhanced engagement with tumor cells potentiated TRAIL to trigger death receptor-dependent apoptosis signaling, even in TRAIL-resistant tumor cells. Building on this success, we constructed F3-HexaTR using the SpyCatcher/SpyTag superglue ligation system to generate a hexameric TRAIL, further amplifying cytotoxicity and antitumor efficacy. Combined analysis of data from TCGA and GTEx revealed significantly elevated NCL expression across 18 solid tumor types, underscoring the clinical potential of F3-directed targeted therapy. These findings highlight that F3-mediated NCL targeting is an effective strategy to overcome tumor penetration barriers, particularly for protein drug delivery. This multivalent assembly approach represents an innovative avenue for enhancing the therapeutic efficacy of various agents in the treatment of solid tumors.Copyright © 2025 Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 药学 2 区 化学:综合
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 药学 2 区 化学:综合
第一作者:
第一作者机构: [1]Division of Liver surgery and NHC Key Lab of Transplant Engineering and Immunology, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China [2]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University, Chengdu 610041, China
共同第一作者:
通讯作者:
通讯机构: [1]Division of Liver surgery and NHC Key Lab of Transplant Engineering and Immunology, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China [2]Sichuan Provincial Engineering Laboratory of Pathology in Clinical Application, West China Hospital, Sichuan University, Chengdu 610041, China [6]Proteomics-Metabolomics Platform, Core facilities, West China Hospital, Sichuan University, Chengdu 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59504 今日访问量:0 总访问量:4869 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号